OCT is a next generation cannabinoid-based pharmaceutical firm
Highlights
- OCT's vision is to become a global leader in cannabinoid prescription medicine, working with world-class partners on research and development, and developing medication that improves the quality of life for patients
- Whilst changes in legislation have resulted in the creation of cannabis markets across the world, there remains a market opportunity for the creation of cannabinoid-based licensed medicines, that are taken through traditional development routes of pharmaceutical drug development
- Kingsley founded OCT after agreeing a research partnership with Oxford University. Since then, the company has completed several rounds of funding, including from FTSE 100 company Imperial Brands PLC. In May 2021, OCT completed an IPO on the Main Market of the London Stock Exchange
- OCT has a lead compound in development for several therapeutic indications, which has Phase 1 clinical trials for its primary indication, Chemotherapy Induced Peripheral Neuralgia
- OCT also has a library of over 400 cannabinoid derivative compounds, both developed internally and licensed from cannabis conglomerate Canopy Growth Corporation
- In August 2023, OCT was voted one of the Top 50 Best Places To Work by the Sunday Times. Kingsley remains the largest shareholder of the business
Kingsley Capital has played a pivotal role in the development of OCT, from its inception, through IPO, and into the clinical stage biopharmaceutical company we’ve now become. Their support has been crucial in developing our equity story and advancing our important mission to harness the therapeutic power of cannabinoids to help people living with debilitating conditions.
Clarissa Sowemimo-Coker
CEO
OCT Press Releases